Start-up will focus on medicines for neural circuit dysfunction


Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference.

The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation.

Sania’s technology platforms were first developed at University College London (UCL) by the company’s co-founders. The launch follows the closing of an oversubscribed Series Seed financing, proceeds of which have been applied to platform development, advancing a lead programme in motor disorders.

The co-founders are Andy Murray, CEO, former Group Leader of Sainsbury Wellcome Centre for Neural Circuits and Behaviour (SWC), UCL, Professor Robert Brownstone, Chair of Neurosurgery at UCL, and Dr Raj S Dattani, Senior Drug Development Clinician at Weatherden.

“We formed Sania with a simple yet powerful vision: to be the first in developing medicines that treat disorders of neural circuits selectively. Today we are excited to demonstrate proof-of-principle data and unveil our platforms,” said Andy Murray.

Sania’s R-Scan platform uses the combination of microfluidics with human induced pluripotent stem cells to recreate human neural circuits in a dish, enabling the directed evolution of human-centric AAVs. A second platform, Gre-Scan, is designed for the high throughput screening of gene regulatory elements.

Neu-Scan facilitates tuneable genetic neuromodulation through the testing and validation of the overexpression of conditionally-activated ion channels.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free